NASDAQ$ARVN
Arvinas Inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Arvinas reported financial results for the third quarter ended September 30, 2021, and provided a corporate update, highlighting the collaboration with Pfizer and progress in clinical trials.
Arvinas reported Q3 2021 financial results, including revenues of $9.3 million and a net loss of $46.8 million. The company highlighted its collaboration with Pfizer and advancements in its clinical-stage programs, particularly ARV-471 and ARV-110.
- Initiated Phase 1b combination trial with ARV-110 and abiraterone for mCRPC.
- Completed global collaboration with Pfizer, receiving $650 million upfront and a $350 million equity investment.
- Cash, cash equivalents, restricted cash and marketable securities were $1,549.0 million as of September 30, 2021.
- Intends to initiate the Phase 1b combination study with everolimus, potentially as part of a planned umbrella study with multiple combination agents with Pfizer, as well as the neoadjuvant study, in 2022.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$9.28M
Revenue by segment
Arvinas · $9.3M total across 1 segment · Q3 2021
- Collaboration Revenue$9.3M+22.4%100.0%
Forward guidance
Arvinas anticipates several milestones, including presenting data from ARV-471 and ARV-110 trials, initiating Phase 3 trials for ARV-471, and announcing Phase 1 data for ARV-766.
Tailwinds
- Present Phase 1 dose escalation trial data (San Antonio Breast Cancer Symposium, December 2021)
- Present data from the VERITAC Phase 2 expansion trial (200 and 500 mg) (2022)
- Present safety data from the Phase 1b combination study with palbociclib (2022)
- Initiate multiple Phase 3 trials in metastatic breast cancer (as monotherapy and in combination) (2022)
- Initiate Phase 1b combination trial with everolimus in 2L/3L metastatic breast cancer, potentially as part of a planned umbrella study with Pfizer to explore multiple combination agents (2022)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro